



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Evaluation of the Role of Serum Vimentin as a Diagnostic Biomarker for Hepatocellular Carcinoma

Thesis

For Partial Fulfillment of Master Degree
in **Gastroenterology and Hepatology**

By

Yousef El Sayed Mohamed El Sayed

M.B.B.Ch., 2014

Under supervision of

Prof. Dr. Amira Ahmed Salem

*Professor of Gastroenterology and Hepatology
Faculty of Medicine – Ain Shams University*

Dr. Manal Sabry Mohamed

*Assistant Professor of Gastroenterology and Hepatology
Faculty of Medicine – Ain Shams University*

Dr. Ahmed Magdy Fathallah

*Lecturer of Gastroenterology and Hepatology
Faculty of Medicine – Ain Shams University*

Faculty of Medicine
Ain Shams University
2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Amira Ahmed Salem**, Professor of Gastroenterology and Hepatology - Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Manal Sabry Mohamed**, Assistant Professor of Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Ahmed M. F. Mansour**, Lecturer of Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Yousef El Sayed Mohamed El Sayed

List of Contents

Title	Page No.
List of Tables	ii
List of Figures	iii
List of Abbreviations	v
Introduction.....	1
Aim of the Work.....	4
Review of Literature	
Hepatocellular Carcinoma	5
Alpha-Fetoprotein in HCC Diagnosis	26
Overview of Different New Biomarkers for HCC	30
Vimentin in HCC Diagnosis.....	33
Patients and Methods.....	41
Results.....	46
Discussion.....	54
Summary.....	64
Conclusion	67
References.....	68
Arabic Summary	---

List of Tables

Table No.	Title	Page No.
Table (1):	Age distribution among the study groups	46
Table (2):	Comparison between the study groups regarding gender	47
Table (3):	Comparison between the study groups regarding laboratory investigation.....	48
Table (4):	Post hoc test between the study groups regarding Hb and platelets.....	48
Table (5):	Comparison between the study groups regarding laboratory investigation.....	49
Table (6):	Comparison between the study groups AFP and Vimentin levels.	50
Table (7):	Post hoc test between the study groups regarding Hb and platelets.....	50
Table (8):	Spearman correlation between AFP and Vimentin levels in the studied groups	52
Table (9):	AUC, Sensitivity, specificity	52

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Percentage Difference in Age-Standardised Incidence Rates per 100,000 Population, 2013-2017.	6
Figure 2:	Incidence of hepatocellular carcinoma (HCC; per 100,000 person-years) by age group in (A) males, and (B) females.....	6
Figure 3:	Histological aspects of normal liver, cirrhotic liver, and hepatocellular carcinoma (HCC).....	15
Figure 4:	Processes involved in HCC	18
Figure 5:	(A) Axial dynamic non-enhanced, (B) Late arterial phase, (C) Portal venous phase	22
Figure 6:	Sensitivities and specificities according to alpha-fetoprotein (AFP) cut-offs values for hepatocellular carcinoma (HCC) diagnosis. 1 Adapted from (Franco et al., 2001).....	28
Figure 7:	Human HCC samples differentiated HCC with E-cadherin localizes at adhering cell-cell junctions, while poorly differentiated HCC show either redistribution of E-cadherin to the cytoplasm or loss of its expression (Giannelli et al., 2016).	34
Figure 8:	(A) vimentin conducted by immunohistochemistry in HCC tissues and adjacent normal tissues, (B) vimentin mRNA level was performed in HCC tissues and adjacent normal tissues by RT-qPCR.....	36
Figure 9:	Vimentin expression was significantly lower in adjacent non-tumoral liver tissues than in primary HCC	38
Figure 10:	The positive rate of tumors that expressed vimentin in the main tumor, the root of the PVTT and the tip of the PVTT	39
Figure 11:	Vimentin (positive vs. negative expression), based on tumor immunostaining.....	40

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure 12:	Box-plot showing difference between the study groups regarding Vimentin level.....	51
Figure 13:	ROC curve of S. Vimentin as a predictor between patients and control	53

List of Abbreviations

Abb.	Full term
<i>18F-FDG</i>	<i>18F-fluorodeoxyglucose</i>
<i>AFB1</i>	<i>Aflatoxin B1</i>
<i>AFP</i>	<i>Alpha-fetoprotein</i>
<i>AFP-L3</i>	<i>Alpha-fetoprotein</i>
<i>ALT</i>	<i>Alanine transaminase</i>
<i>ANG-2</i>	<i>Angiopoietin 2</i>
<i>AST</i>	<i>Aspartate transaminase</i>
<i>BM</i>	<i>Bone marrow</i>
<i>BSA</i>	<i>Bovine Serum Albumin</i>
<i>CBC</i>	<i>Complete Blood Count</i>
<i>CEUS</i>	<i>Contrast-enhanced US</i>
<i>CLD</i>	<i>Chronic liver disease</i>
<i>CTCs</i>	<i>Circulating tumor cells</i>
<i>DCP</i>	<i>Des-gamma-carboxy prothrombin</i>
<i>ECM</i>	<i>Extracellular matrix</i>
<i>EMT</i>	<i>Epithelial-to-mesenchymal transition</i>
<i>GP73</i>	<i>Golgi glycoprotein 73</i>
<i>Gp-73</i>	<i>Golgi protein 73</i>
<i>HBV</i>	<i>Hepatitis B virus</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HGF</i>	<i>Hepatic growth factor</i>
<i>HRP</i>	<i>Horseradish Peroxidase</i>
<i>HSCs</i>	<i>Hepatic stellate cells</i>
<i>IF</i>	<i>Intermediate filament</i>
<i>IGF-1</i>	<i>Insulin growth factor-1</i>
<i>INR</i>	<i>International randomized ratio</i>
<i>LCA</i>	<i>Lens culinaris agglutinin</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>NAFLD</i>	<i>Non-alcoholic fatty liver disease</i>
<i>NASH</i>	<i>Non-alcoholic steatohepatitis</i>
<i>OPN</i>	<i>Glypican-3 osteopontin</i>
<i>PC</i>	<i>Prothrombin concentration</i>
<i>PET</i>	<i>Positron emission tomography</i>
<i>PME</i>	<i>Premalignant environment</i>
<i>PVTT</i>	<i>Portal vein tumor thrombus</i>
<i>ROS</i>	<i>Reactive oxygen species</i>
<i>SPSS</i>	<i>Statistical Package for Social Sciences software</i>
<i>TICs</i>	<i>Tumor-initiating cells</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>

INTRODUCTION

Hepatocellular carcinoma (HCC) is a major unresolved medical issue, which is considered as the seventh most common cancer globally and the fourth leading cause of cancer deaths, with approximately 700,000 deaths per year (**Fitzmaurice et al., 2018**).

Multiple risk factors can trigger HCC development and progression, including viral hepatitis B and C infection, chronic alcohol consumption, metabolic disorders, and age (**Ghouri et al., 2017**).

The chief causes of HCC are liver fibrosis or cirrhosis from chronic viral infections. Because cases tend to arise from preceeding pathologies, biomarker surveillance in high-risk individuals is an indispensable tool for achieving earlier detection and improved outcomes of HCC (**Black and Mehta, 2018**).

A 2017 update of the AASLD guidelines recommends surveillance using ultrasonography, with or without α -fetoprotein (AFP), every six months (**Heimbach et al., 2018**).

Surveillance strategies in patients at a higher risk of HCC have led to the diagnosis of the disease at much earlier stages. Patients in the early stages have a much higher chance of curative response with different treatment options. While surgery is the most effective treatment for liver tumors, about 80% of HCCs are

not curable at presentation, and therefore the patients die due to the delayed diagnosis **(Black and Mehta, 2018)**.

Although numerous efforts have been made to discover more reliable biomarkers for the diagnosis of HCC such as AFP-L3, DCP and GP73, serum AFP remains the most commonly used biomarker **(Chaiteerakij et al., 2015)**.

AFP is a glycoprotein, physiologically synthesized during the early stages of fetal liver development by the endodermal cells of the visceral yolk sac. The AFP expression by hepatocytes and endodermal cells of the yolk sac reduces after birth. The elevation of AFP can occur in hepatocyte regeneration, during hepato-carcinogenesis, and embryonic carcinomas **(Biondi et al., 2012)**.

Serum concentrations of AFP have been shown to be the most useful tumor marker with regards to HCC but levels may be normal in up to 40% of patients, reducing its sensitivity. Moreover, it may be increased in patients with hepatitis and cirrhosis, compromising its specificity **(Lersritwimanmaen and Nimanong, 2018)**.

It has recently been shown that most small HCC nodules do not increase AFP levels, decreasing the sensitivity of AFP for tumors smaller than 3 cm to just 25% **(Shu et al., 2017)**.

Vimentin is classified as a type III intermediate filament (IF) protein. Its function is to maintain cellular integrity and

protect the cell against stress. It is the major cytoskeletal component of mesenchymal cells. It also plays a significant role in cell shape maintenance and in stabilizing cytoskeletal interactions **(Roggiani and Gouliau, 2015)**.

Vimentin expression in tumor cells has been recognized as a hallmark of epithelial- mesenchymal transition (EMT), and is associated with cell invasion and poor prognosis **(Satelli et al., 2017)**.

Meng et al. (2018) reported that vimentin was involved in the process of EMT in HCC and that its down-regulation inhibits EMT.